search
Back to results

Virtual Communication in the Hospital: Impact on Patients and Surrogates (VCHIPS)

Primary Purpose

Communication, Anxiety, Depression

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
VCHIPS
Sponsored by
Indiana University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Communication

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patient:

  • 65 years or older
  • cognitive impairment due to ADRD, delirium, or other causes of cognitive impairment severe enough that they require a surrogate for all medical decisions
  • must have a surrogate decision maker based on a previously executed healthcare representative form or based on Indiana statute.

Surrogate:

  • English-speaking
  • Surrogate does not plan to be at patient's bedside every day
  • surrogate is 18 or older

Exclusion Criteria:

Patient:

  • Less than 65 years old
  • Incarcerated individuals (e.g. prisoners)
  • Lack of cognitive impairment
  • Terminal wean/ actively dying

Surrogate:

  • Less than 18 years old
  • Incarcerated individuals (e.g. prisoners)
  • non-English speaking
  • plans to be at patient's bedside every day
  • has a care contract or flagged for security risk
  • state-appointed guardians

Sites / Locations

  • Indiana University Health

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Usual Care: Control Group

VCHIPS: Intervention Group

Arm Description

No interventions administered. Participant will receive usual care in the hospital.

Individuals in this group will work with a study nurse to schedule the intervention.

Outcomes

Primary Outcome Measures

Measure change in ratings of communication quality among study participants using the FICS at baseline, 6-8 weeks after patient discharge, and 6 months after patient discharge
Communication quality will be measured using the validated Family Inpatient Communication Survey (30 item scale)

Secondary Outcome Measures

Measure change in participant depression among study participants using the PHQ-8 at baseline, 6-8 weeks after discharge, and 6 months after discharge
Depression will be measured using the validated Patient Health Questionnaire (8 item)
Measure change in anxiety among study participants using the GAD-7 at baseline, 6-8 weeks after discharge, and 6 months after discharge
Anxiety will be measured using the validated Generalized Anxiety Disorder-7
Measure change in the impact of events among study participants using the IES-R at 6-8 weeks after discharge and 6 months after discharge
Impact of Events will be measured using the validated Impact of Events Scale
Measure complicated grief for study participants of patients who died at 6 months after discharge
Complicated grief will be measured using the validated Inventory of Complicated Grief
Measure change in participants' ratings of communication quality over time for the duration of the patient's hospital stay
Communication quality will be measured from participants responses to texted survey questions (ecological momentary assessment) written by the study team. Participants will respond on a 5 point Likert scale.

Full Information

First Posted
April 15, 2022
Last Updated
August 31, 2023
Sponsor
Indiana University
Collaborators
National Institute on Aging (NIA), National Institutes of Health (NIH), Indiana University Health, Regenstrief Institute, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05395039
Brief Title
Virtual Communication in the Hospital: Impact on Patients and Surrogates
Acronym
VCHIPS
Official Title
Communication in the Hospital: Impact on Patients With Alzheimer's Disease and Other Causes of Cognitive Impairments and Their Surrogate Decision Makers
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Withdrawn
Why Stopped
Recruitment effort yielded no enrollments, so this study was stopped. We are re-evaluating the study design.
Study Start Date
December 1, 2023 (Anticipated)
Primary Completion Date
May 31, 2024 (Anticipated)
Study Completion Date
May 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indiana University
Collaborators
National Institute on Aging (NIA), National Institutes of Health (NIH), Indiana University Health, Regenstrief Institute, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a pilot study of scheduled video/audio conferences by clinical navigators on the experience of surrogate decision makers for hospitalized older adults with Alzheimer's disease (AD), delirium, and other causes of cognitive impairment. The purpose of this study is to learn more about the experiences of surrogate decision makers of hospitalized older adults when they cannot be physically present with the patient in the hospital. We will conduct a randomized pilot study of virtual visits to connect the surrogate decision makers of incapacitated, hospitalized older adults with AD, delirium, and related causes of cognitive impairment with the patient and clinicians.
Detailed Description
As the COVID-19 pandemic exploded, hospitals across the globe completely excluded or severely limited family visitors. Thousands of patients have faced life-threatening illness or died without any loved ones at the bedside. Patients with AD were often unable to understand why their family members could not be present, leading to increased agitation. The calming presence that family often provide to hospitalized patients was missing. In addition to the tragedy for patients, family members were forced to address decisions about life-sustaining treatments without being able to see the patient or talk face to face with clinicians. As our knowledge of coronavirus transmission expanded, visitor restrictions have been relaxed in some cases but not eliminated. Urgent interventions are needed to mitigate the harm of these restrictions. While the future is uncertain, COVID-19 cases are rising across the country, suggesting that visitation will continue to be restricted. Additionally, our tertiary referral center often admits patients from across the state, limiting the ability of family members to be at the bedside. Harnessing virtual technologies has the potential to enhance surrogate/clinician communication and decision making during the pandemic and after. Telehealth has greatly expanded the abilities of patients to see clinicians remotely or for clinician to clinician consultation, but prior to COVID-19 there were few interventions aimed at the family members of hospitalized patients. We feel we are poised to rapidly move along the NIH research pathway given that we are studying our early implementation. At the conclusion of this pilot, we will then conduct an effectiveness trial, followed by an embedded, pragmatic clinical trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Communication, Anxiety, Depression, Distress, Emotional

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Intervention Group: VCHIPS Control Group: Usual care
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Usual Care: Control Group
Arm Type
No Intervention
Arm Description
No interventions administered. Participant will receive usual care in the hospital.
Arm Title
VCHIPS: Intervention Group
Arm Type
Experimental
Arm Description
Individuals in this group will work with a study nurse to schedule the intervention.
Intervention Type
Other
Intervention Name(s)
VCHIPS
Intervention Description
Participants in this group will have the opportunity to receive virtual visits with the patient during the hospital stay, led by a study nurse.
Primary Outcome Measure Information:
Title
Measure change in ratings of communication quality among study participants using the FICS at baseline, 6-8 weeks after patient discharge, and 6 months after patient discharge
Description
Communication quality will be measured using the validated Family Inpatient Communication Survey (30 item scale)
Time Frame
6-8 weeks after discharge, 6 months after discharge
Secondary Outcome Measure Information:
Title
Measure change in participant depression among study participants using the PHQ-8 at baseline, 6-8 weeks after discharge, and 6 months after discharge
Description
Depression will be measured using the validated Patient Health Questionnaire (8 item)
Time Frame
Baseline, 6-8 weeks after discharge, 6 months after discharge
Title
Measure change in anxiety among study participants using the GAD-7 at baseline, 6-8 weeks after discharge, and 6 months after discharge
Description
Anxiety will be measured using the validated Generalized Anxiety Disorder-7
Time Frame
Baseline, 6-8 weeks after discharge, 6 months after discharge
Title
Measure change in the impact of events among study participants using the IES-R at 6-8 weeks after discharge and 6 months after discharge
Description
Impact of Events will be measured using the validated Impact of Events Scale
Time Frame
6-8 weeks after discharge, 6 months after discharge
Title
Measure complicated grief for study participants of patients who died at 6 months after discharge
Description
Complicated grief will be measured using the validated Inventory of Complicated Grief
Time Frame
6 months after death
Title
Measure change in participants' ratings of communication quality over time for the duration of the patient's hospital stay
Description
Communication quality will be measured from participants responses to texted survey questions (ecological momentary assessment) written by the study team. Participants will respond on a 5 point Likert scale.
Time Frame
Communication quality will be measured daily during the first week and twice a week thereafter for the duration of the hospital stay, up to 1 year
Other Pre-specified Outcome Measures:
Title
Measure the change in observable and/or reported level of pain in patients of participants in the intervention group.
Description
Clinical measures will be obtained through direct observation of the patient by study nurses using the PAINAD scale or through patient self-report using the FACES Pain Scale
Time Frame
Pre/post observations of pain will occur at the time of study intervention, typically within 1 hour.
Title
Measure the change in observable and/or reported level of distress in patients in the intervention group before and after study intervention
Description
Clinical measures will be obtained by study nurses using the distress thermometer for patients who are able to self-report.
Time Frame
Pre/post observations of distress will occur at the time of study intervention, typically within 1 hour of each other.
Title
Measure the change in blood pressure in patients in the intervention group before and after study intervention
Description
The nurse will obtain the patient's blood pressure before and after the intervention
Time Frame
Pre/post observations of blood pressure will occur at the time of study intervention, typically within 1 hour of each other.
Title
Measure the change in heart rate in patients in the intervention group before and after study intervention
Description
The nurse will obtain the patient's heart rate before and after the intervention
Time Frame
Pre/post observations of heart rate will occur at the time of study intervention, typically within 1 hour of each other.
Title
Measure the change in respiratory rate in patients in the intervention group before and after study intervention
Description
The nurse will obtain the patient's respiratory rate before and after the intervention
Time Frame
Pre/post observations of respiratory rate will occur at the time of study intervention, typically within 1 hour of each other.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient: 65 years or older cognitive impairment due to ADRD, delirium, or other causes of cognitive impairment severe enough that they require a surrogate for all medical decisions must have a surrogate decision maker based on a previously executed healthcare representative form or based on Indiana statute. Surrogate: English-speaking Surrogate does not plan to be at patient's bedside every day surrogate is 18 or older Exclusion Criteria: Patient: Less than 65 years old Incarcerated individuals (e.g. prisoners) Lack of cognitive impairment Terminal wean/ actively dying Surrogate: Less than 18 years old Incarcerated individuals (e.g. prisoners) non-English speaking plans to be at patient's bedside every day has a care contract or flagged for security risk state-appointed guardians
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexia M Torke, MD
Organizational Affiliation
Indiana University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Indiana University Health
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Virtual Communication in the Hospital: Impact on Patients and Surrogates

We'll reach out to this number within 24 hrs